A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intermittent Preventive Treatment of Malaria in Children (IPTc)

London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLoS ONE (Impact Factor: 3.23). 02/2011; 6(2):e16976. DOI: 10.1371/journal.pone.0016976
Source: PubMed


Intermittent preventive treatment of malaria in children less than five years of age (IPTc) has been investigated as a measure to control the burden of malaria in the Sahel and sub-Sahelian areas of Africa where malaria transmission is markedly seasonal.
IPTc studies were identified using a systematic literature search. Meta-analysis was used to assess the protective efficacy of IPTc against clinical episodes of falciparum malaria. The impact of IPTc on all-cause mortality, hospital admissions, severe malaria and the prevalence of parasitaemia and anaemia was investigated. Three aspects of safety were also assessed: adverse reactions to study drugs, development of drug resistance and loss of immunity to malaria. Twelve IPTc studies were identified: seven controlled and five non-controlled trials. Controlled studies demonstrated protective efficacies against clinical malaria of between 31% and 93% and meta-analysis gave an overall protective efficacy of monthly administered IPTc of 82% (95%CI 75%-87%) during the malaria transmission season. Pooling results from twelve studies demonstrated a protective effect of IPTc against all-cause mortality of 57% (95%CI 24%-76%) during the malaria transmission season. No serious adverse events attributable to the drugs used for IPTc were observed in any of the studies. Data from three studies that followed children during the malaria transmission season in the year following IPTc administration showed evidence of a slight increase in the incidence of clinical malaria compared to children who had not received IPTc.
IPTc is a safe method of malaria control that has the potential to avert a significant proportion of clinical malaria episodes in areas with markedly seasonal malaria transmission and also appears to have a substantial protective effect against all-cause mortality. These findings indicate that IPTc is a potentially valuable tool that can contribute to the control of malaria in areas with markedly seasonal transmission.

Download full-text


Available from: Anne Wilson
  • Source
    • "Antimalarial drug resistance is a major public health problem which hinders the control of malaria even at attempting some multistage, multivalented vaccines (Yang et al., 2009; Nnamani et al., 2011). Resistance is occurring as a consequence of several factors, including poor treatment practices, inadequate patient adherence to prescribed antimalarial regimens, widespread availability of artemisinin-based monotherapies, and substandard forms of the drug (Thiam et al., 2011; Wilson, 2011). In recent years, parasite resistance to artemisinins – the key compounds in artemisinin combination therapy (ACTs) – has been detected in four countries of the Greater Mekong subregion: Cambodia, 2011a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: NLC topical formulation as an alternative to oral and parenteral (IM) delivery of artemether (ART), a poorly water-soluble drug was designed. A Phospholipon 85G-modified Gelucire 43/01 based NLC formulation containing 75% Transcutol was chosen from DSC studies and loaded with gradient concentration of ART (100–750 mg). ART-loaded NLCs were stable (À22 to À40 mV), polydispersed (0.4–0.7) with d90 size distribution range of 247–530 nm without microparticles up to one month of storage. The encapsulation efficiency (EE%) for ART in the NLC was concentration independent as 250 mg of ART loading achieved $61%. DSC confirmed molecular dispersion of ART due to low matrix crystallinity (0.028 J/g). Ex vivo study showed detectable ART amounts after 20 h which gradually increased over 48 h achieving $26% cumulative amount permeated irrespective of the applied dose. This proves that ART permeates excised human epidermis, where the current formulation served as a reservoir to gradually control drug release over an extended period of time. Full thickness skin study therefore may confirm if this is a positive signal to hope for a topical delivery system of ART. ã 2014 Elsevier B.V. All rights reserved.
    Full-text · Article · Oct 2014 · International Journal of Pharmaceutics
  • Source
    • "In such areas, administration of IPT to children (IPTc) 3 months to 5 years of age monthly during the seasonal peak in malaria transmission seems like an attractive strategy in preventing malaria. A meta-analysis of 12 clinical IPTc studies in sub-Saharan Africa including Senegal using SP, but always combined with another drug (amodiaquine AQ), have demonstrated impressive protective efficacies against clinical malaria episodes ranging from 31% to 93% (overall protective efficacy of 82% (95% CI = 75–87%).9 Furthermore, it was shown that IPTc protected against all-cause mortality by 57% (95% CI = 24–76%).9 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Our study investigated the possible impact of SP-IPT given to infants and children on the prevalence of SP-resistant haplotypes in the Plasmodium falciparum genes Pfdhfr and Pfdhps, comparing sites with and without IPTi/c. P. falciparum positive samples (N = 352) collected from children < 5 years were analyzed to determine the prevalence of SP resistance-related haplotypes by nested PCR followed by sequence-specific oligonucleotide probe-enzyme-linked immunosorbent assay. The prevalence of the Pfdhfr triple mutant haplotype (CIRN) increased in both groups, but only significantly in the IPTi/c group from 41% to 65% in 2011 (P = 0.005). Conversely, the Pfdhps 437G mutation decreased in both groups from 44.6% to 28.6% (P = 0.07) and from 66.7% to 47.5% (P = 0.02) between 2010 and 2011 in the control and the IPTi/c groups, respectively. A weak trend for decreasing prevalence of quadruple mutants (triple Pfdhfr + Pfdhps 437G) was noted in both groups (P = 0.15 and P = 0.34). During the two cross-sectional surveys some significant changes were observed in the SP resistance-related genes.
    Full-text · Article · Apr 2013 · The American journal of tropical medicine and hygiene
  • Source
    • "The symptomatic inhabitants were treated according to the Brazilian Health Ministry protocol [26]. Thus, P. falciparum infection was treated with artemether-lumefantrine, Coartem [32] [33], while P. vivax infection was treated with CQ (25 mg/kg base over 3 days: 10.0 mg/kg on day 1, and 7.5 mg/kg on days 2 and 3) plus PQ (0.5 mg/kg/day for 7 days) for seven days (short scheme), and adjusted for patient weight [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In children, the Intermittent Preventive Treatment (IPTc), currently called Seasonal Malaria Chemoprevention (SMC), was considered effective on malaria control due to the reduction of its incidence in Papua New Guinea and in some areas with seasonal malaria in Africa. However, the IPT has not been indicated because of its association with drug resistance and for hindering natural immunity development. Thus, we evaluated the alternative IPT impact on malaria incidence in three riverside communities on Madeira River, in the municipality of Porto Velho, RO. We denominate this scheme Selective Intermittent Preventive Treatment (SIPT). The SIPT consists in a weekly dose of two 150 mg chloroquine tablets for 12 weeks, for adults, and an equivalent dose for children, after complete supervised treatment for P. vivax infection. This scheme is recommend by Brazilian Health Ministry to avoid frequent relapses. The clinic parasitological and epidemiological surveillance showed a significant reduction on vivax malaria incidence. The results showed a reduction on relapses and recurrence of malaria after SIPT implementation. The SIPT can be effective on vivax malaria control in localities with high transmission risk in the Brazilian Amazon.
    Full-text · Article · Mar 2013 · Malaria Research and Treatment
Show more